GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)

GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)

Issued: Tuesday 15 June 2010

GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a conditional marketing authorisation for Votrient® (pazopanib) for the first-line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. As part of these conditions, GSK will provide data from ongoing clinical studies.

The US Food and Drug Administration (FDA) approved the use of Votrient® (pazopanib) as a treatment for patients with advanced RCC in October 2009.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.